Merit Medical Systems (NASDAQ:MMSI) Price Target Raised to $83.00 at Wells Fargo & Company

Merit Medical Systems (NASDAQ:MMSI) had its target price lifted by equities researchers at Wells Fargo & Company from $74.00 to $83.00 in a report issued on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target points to a potential downside of 0.15% from the company’s previous close.

Several other brokerages also recently commented on MMSI. Raymond James Financial reaffirmed an “outperform” rating on shares of Merit Medical Systems in a research report on Friday. Barrington Research cut their target price on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating on the stock in a research note on Monday, April 20th. Weiss Ratings cut shares of Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. JPMorgan Chase & Co. decreased their price target on shares of Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Finally, Wall Street Zen lowered shares of Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $96.56.

Merit Medical Systems Trading Down 0.3%

Shares of Merit Medical Systems stock traded down $0.23 on Friday, hitting $83.12. 427,913 shares of the company’s stock traded hands, compared to its average volume of 797,398. The company has a fifty day moving average of $69.45 and a two-hundred day moving average of $71.69. Merit Medical Systems has a one year low of $59.74 and a one year high of $94.75. The company has a market capitalization of $4.96 billion, a price-to-earnings ratio of 36.07, a price-to-earnings-growth ratio of 2.51 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46.

Merit Medical Systems (NASDAQ:MMSI) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The business had revenue of $418.84 million during the quarter, compared to the consensus estimate of $405.25 million. During the same period in the previous year, the company posted $1.01 earnings per share. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, sell-side analysts expect that Merit Medical Systems will post 3.62 earnings per share for the current year.

Insider Activity at Merit Medical Systems

In other news, insider Brian G. Lloyd bought 2,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were bought at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the acquisition, the insider directly owned 2,000 shares in the company, valued at approximately $125,240. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lynne N. Ward sold 5,000 shares of Merit Medical Systems stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the completion of the sale, the director directly owned 7,809 shares of the company’s stock, valued at approximately $488,921.49. The trade was a 39.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.70% of the company’s stock.

Institutional Trading of Merit Medical Systems

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in shares of Merit Medical Systems in the 4th quarter worth about $1,537,000. Bessemer Group Inc. increased its holdings in Merit Medical Systems by 54.2% during the 4th quarter. Bessemer Group Inc. now owns 313,981 shares of the medical instruments supplier’s stock worth $27,674,000 after purchasing an additional 110,392 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Merit Medical Systems in the fourth quarter worth approximately $12,239,000. Norges Bank purchased a new stake in shares of Merit Medical Systems in the fourth quarter worth approximately $75,957,000. Finally, Peak Retirement Planning Inc. lifted its holdings in shares of Merit Medical Systems by 35.4% in the fourth quarter. Peak Retirement Planning Inc. now owns 32,472 shares of the medical instruments supplier’s stock valued at $2,862,000 after purchasing an additional 8,494 shares in the last quarter. Institutional investors own 99.66% of the company’s stock.

Key Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Non-GAAP EPS was $1.19, well above the $0.96 consensus and up from $1.01 a year earlier. Revenue increased 9.5% year over year to $418.8 million, beating estimates of $405.3 million. Merit Medical surpasses Q2 earnings and revenue estimates
• Positive Sentiment: Management raised its full-year outlook. Merit now expects 2026 EPS of $4.25–$4.35, above the roughly $3.98 analyst consensus, while revenue guidance is approximately $1.6 billion. The company also reported improved GAAP and non-GAAP operating margins in the quarter. Merit Medical reports Q2 results and updates guidance
• Positive Sentiment: Analysts became more bullish. Needham raised its price target from $90 to $101 and assigned a Buy rating, while BTIG lifted its target from $100 to $105 and maintained a Buy rating. The revisions reinforce expectations that the earnings beat and guidance increase could support further gains for MMSI. Needham raises Merit Medical price target
• Negative Sentiment: Cash generation was weaker year to date. Operating cash flow declined 11% to $110.0 million and free cash flow fell 14% to $76.6 million, a potential concern despite the stronger profit outlook. Merit Medical second-quarter financial highlights

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.